Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective.

J Mol Med (Berl) · 2022 · PMC9126699 · PMID 35606652

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Robust and optimised manufacturing processes which meet all regulatory release requirements are well established for GMP adenoviral vector production, and the recent COVID-19 pandemic has demonstrated the highly significant potential that gene transfer vectors based on adenoviruses have for use as mass medicines in the human population.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.